Idarucizumab: What Should We Know?, PMID: 28950812
Idarucizumab for Dabigatran Reversal, PMID: 26095746
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis, PMID: 28693366
Idarucizumab, PMID: 27789932
Idarucizumab for the Reversal of Dabigatran, PMID: 28110992
Idarucizumab, PMID: 29999814
Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review, PMID: 27175894
idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote, PMID: 30715821
Idarucizumab: A Review as a Reversal Agent for Dabigatran, PMID: 27388764
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation, PMID: 27389324
Idarucizumab (Praxbind) Formulary Review, PMID: 27465000
Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds, PMID: 30715945
Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience, PMID: 30203330
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons, PMID: 30686041
Idarucizumab: First Global Approval, PMID: 26578027
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran, PMID: 27274201
Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study, PMID: 32691242
Evidence supporting idarucizumab for the reversal of dabigatran, PMID: 27697436
Evidence Supporting Idarucizumab for the Reversal of Dabigatran, PMID: 27568285
Idarucizumab for dabigatran reversal in daily clinical practice: A case series, PMID: 32175987
Reversal of dabigatran by idarucizumab: when and how?, PMID: 27166653
Idarucizumab before reperfusion therapy in stroke patients on dabigatran: No more cold sweat, PMID: 32079736
Dabigatran reversal with idarucizumab prior to lung transplantation, PMID: 33150658
Assessment of patients post reversal with idarucizumab, PMID: 30120649
[Experience with idarucizumab as a reverse agent of dabigatran], PMID: 32841148
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal, PMID: 30174430
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum, PMID: 30916798
Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice, PMID: 31470446
Three-month use of idarucizumab at Christchurch Hospital through the emergency department and MedChartTM, PMID: 31352470
Idarucizumab: The Antidote for Reversal of Dabigatran, PMID: 26700008
Idarucizumab (Praxbind)--an antidote for dabigatran, PMID: 26583604
Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series, PMID: 31662218
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, PMID: 30703431
Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran, PMID: 26894245
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding, PMID: 30586692
Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program, PMID: 31470445
Real-world experience with reversal of dabigatran by idarucizumab, PMID: 33227654
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment, PMID: 31582135
Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort, PMID: 32079737
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study, PMID: 32152956
Anticoagulation Reversal, PMID: 30037445
Idarucizumab in the 'real world': possibilities and limitations, PMID: 30364967
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects, PMID: 27707528
Performance of idarucizumab as antidote of dabigatran in daily clinical practice, PMID: 30339226
Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study, PMID: 31332727
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols, PMID: 27569673
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran, PMID: 31050868
Drugs for atrial fibrillation, PMID: 31599871
Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran, PMID: 27477871
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols, PMID: 27697438
Diagnostics and management of direct oral anticoagulants-induced bleeding., PMID:40493531
Sonorheometry parameters during dabigatran reversal with idarucizumab for major bleeding., PMID:40466460
2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management., PMID:40448969
Intravenous Dabigatran Provides Effective, Reversible Anticoagulation for Cardiopulmonary Bypass in a Sheep Model., PMID:40424620
Reversal of anticoagulation in patients with intracerebral haemorrhage related to oral anticoagulants: State of the evidence., PMID:40401655
Safety of direct oral anticoagulants reversal agents in older patients: an analysis of individual case safety reports of adverse drug reaction from VigiBase®., PMID:40192996
Andexanet Alfa in Urgent Cardiac Surgery: A Case Report of Edoxaban Reversal for Acute Hemopericardium., PMID:40158195
Pro: The Patient With the Recent Intake of DOACs Problems Are Solved With the Approval of Reversal Agents., PMID:39984366
Two Cases of Pseudoelevation of Plasma Thrombin Time Levels., PMID:39967546
Con: The Patient With Recent Intake of Direct Oral Anticoagulants-Problems Are Not Solved With the Approval of Reversal Agents., PMID:39952835
Correction of the effect of direct oral and parenteral anticoagulants in hemorrhagic stroke., PMID:39907674
Intravenous thrombolysis for patients with acute ischemic stroke while receiving a direct oral anticoagulant: A systematic review and meta-analysis., PMID:39831680
Comparative Outcomes of Warfarin vs. Direct Oral Anticoagulants (DOACs) in Anticoagulant-Related Gastrointestinal Bleeding: A Single-Center Study., PMID:39744289
Bleeding Risk of Anticoagulation Reversal Strategies Before Heart Transplantation: A Retrospective Comparative Cohort Study., PMID:39590209
Incidence of Venous Thromboembolism Post-Oral Anticoagulation Reversal in Intracranial Hemorrhage Patients., PMID:39563016
Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report., PMID:39524786
[Current Management of Patients with Proximal Femur Fractures Receiving Antiplatelet and Anticoagulant Therapy]., PMID:39496190
Strategies for Perioperative Anticoagulant Reversal in Orthopedic Surgery: A Review., PMID:39467789
Intravenous thrombolysis following dabigatran reversal in a patient with acute embolic stroke after atrial fibrillation ablation., PMID:39416242
Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis., PMID:39255429
Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran., PMID:39230640
Thrombolysis for Ischemic Stroke Despite Recent Ingestion of Direct Oral Anticoagulants - A Growing Dilemma Also in India., PMID:39196805
Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review., PMID:39133476
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH., PMID:39029742
Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report., PMID:39020273
Anticoagulation and Antiplatelet Regimen in Cardiac Transplant. Clinical Characteristics, Outcomes, and Blood Product Transfusion., PMID:38952201
Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine)., PMID:38926082
[Overdosing of direct oral anticoagulants]., PMID:38916655
Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update., PMID:38817549
ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events., PMID:38784674
Reversal or Repletion Treatment Strategies and Outcomes of Patients With Major Bleeding Events Managed in the Emergency Department: Large Real-Life Investigation in the Northwestern Healthcare District of Tuscany., PMID:38781079
Coagulation Tests and Reversal Agents in Patients Treated with Oral Anticoagulants: The Challenging Scenarios of Life-Threatening Bleeding and Unplanned Invasive Procedures., PMID:38730979
Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?, PMID:38626592
Balfaxar: Another four-factor PCC for warfarin reversal., PMID:38412268
Direct oral anticoagulants in trauma patients., PMID:38390987
Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma., PMID:38390922
Cardiac Tamponade and Duodenal Hemorrhage Caused by Inappropriate Use of Dabigatran in a Patient With End-Stage Renal Failure: A Case Report., PMID:38371033
Latest advances in the reversal strategies for direct oral anticoagulants., PMID:38350629
Barriers in Access to Idarucizumab in Ischemic Stroke in a Middle-Income Country., PMID:38235022
Treatment of atrial fibrillation., PMID:38180321
Dabigatran pharmacokinetic-pharmacodynamic in sheep: Informing dose for anticoagulation during cardiopulmonary bypass., PMID:38171494
Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta-Analysis., PMID:38108256
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines., PMID:38043043
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines., PMID:38033089
Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab., PMID:38028276
Reversing dabigatran effect with idarucizumab to enable intravenous thrombolysis in patients with acute ischaemic stroke - a single centre experience., PMID:37955597
Efficacy and Safety of Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review., PMID:37927673
Evidence-based Management of Major Bleeding in Patients Receiving Direct Oral Anticoagulants: An Updated Narrative Review on the Role of Specific Reversal Agents., PMID:37872658
Treatment of dabigatran intoxication in critically ill patients with Acute Kidney Injury: The role of Sustained Low-Efficiency Dialysis., PMID:37853619
For research use only. Not for human or drug use.
